-
公开(公告)号：EP2004184A2
公开(公告)日：2008-12-24
申请号：EP07781281.6
申请日：2007-04-04
申请人： NOVARTIS AG , Novartis Pharma GmbH
发明人： BURKE, Gregory , LINNARTZ, Ronald, Richard , MCSHEEHY, Paul M.J. , VERSACE, Richard, William , WARTMANN, Markus
IPC分类号： A61K31/425
CPC分类号： A61K31/425 , A61K45/06 , A61K2300/00
摘要： The invention relates to a combination comprising a microtubule active agent; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
-
2.发明授权SUBSTITUTED CAPROLACTAM CARBONATES AND ETHERS AND THEIR USE AS ANTI-TUMOR AGENTS 有权取代碳酸己内酰胺和乙醚及其用途抗肿瘤活性
公开(公告)号：EP1282604B1
公开(公告)日：2008-01-09
申请号：EP01975824.2
申请日：2001-05-09
申请人： Novartis AG , Novartis Pharma GmbH
IPC分类号： C07D223/12 , A61K31/55 , A61P35/00
CPC分类号： C07D223/12
摘要： The present invention relates to certain substituted caporlactam carbonate and ether compounds of following formula (I): pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
-
公开(公告)号：EP1318980B1
公开(公告)日：2007-10-31
申请号：EP01960717.5
申请日：2001-08-30
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BAIR, Kenneth, Walter , GREEN, Michael, A. , PEREZ, Lawrence, B. , REMISZEWSKI, Stacy, W. , SAMBUCETTI, Lidia , VERSACE, Richard, William , SHARMA, Sushil, Kumar
IPC分类号： C07D209/16 , C07C259/06 , C07D417/12 , C07D403/12 , C07D471/04 , C07D519/00 , C07D295/02 , A61K31/4045 , A61K31/16 , A61P35/00
CPC分类号： C07D401/12 , C04B35/632 , C07C259/06 , C07D209/16 , C07D233/64 , C07D295/155 , C07D307/81 , C07D403/12 , C07D405/12 , C07D471/04
摘要： The present invention provides hydroxamate compounds of formula I: which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
-
公开(公告)号：EP1318980A2
公开(公告)日：2003-06-18
申请号：EP01960717.5
申请日：2001-08-30
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BAIR, Kenneth, Walter , GREEN, Michael, A. , PEREZ, Lawrence, B. , REMISZEWSKI, Stacy, W. , SAMBUCETTI, Lidia , VERSACE, Richard, William , SHARMA, Sushil, Kumar
IPC分类号： C07D209/16 , C07C259/06 , C07D417/12 , C07D403/12 , C07D471/04 , C07D519/00 , C07D295/02 , A61K31/4045 , A61K31/16 , A61P35/00
CPC分类号： C07D401/12 , C04B35/632 , C07C259/06 , C07D209/16 , C07D233/64 , C07D295/155 , C07D307/81 , C07D403/12 , C07D405/12 , C07D471/04
摘要： The present invention provides hydroxamate compounds of formula I: which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
-
5.发明授权
公开(公告)号：EP1131297B1
公开(公告)日：2004-04-14
申请号：EP99957309.0
申请日：1999-11-15
申请人： Novartis AG , Novartis Pharma GmbH
发明人： KINDER, Frederick, Ray, Jr. , BAIR, Kenneth, Walter , JAGOE, Christopher, Turchik , VERSACE, Richard, William , WATTANASIN, Sompong
IPC分类号： C07D223/10 , C07D409/12 , C07D403/12 , C07D401/12 , A61K31/55 , A61P35/00
CPC分类号： C07D401/12 , C07D223/10 , C07D403/12 , C07D409/12
摘要： The present invention relates to certain substituted caprolactam compounds of formula (I), where R1 is (C1-6)alkyl or (C3-6)cycloalkyl; R2 is hydrogen or (C1-6)alkyl; X is (C1-12)alkylene; (C2-12)alkenylene; or (C2-12)alkynylene; m is 0 or 1; and R3 is (C3-8)cycloalkyl; or an aromatic ring system selected from (II, III, IV and V), where R4 is hydrogen, chloro, or methoxy; R5 is hydrogen, chloro, (C1-18)alkyl or (C1-18)alkoxy, and Z is oxygen, sulfur, N-H, or N-CH3; or a pharmaceutically acceptable acid addition salt thereof, where possible, pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
-
公开(公告)号：EP1942882A2
公开(公告)日：2008-07-16
申请号：EP06844219.3
申请日：2006-10-23
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： A61K31/165
CPC分类号： A61K31/165
摘要： This invention relates to organic compounds of formula (I): in particular, to pharmaceutical compositions for use in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.
-
7.发明公开1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开1,4-二取代的异喹啉AS Raf激酶抑制剂，其增殖性疾病治疗是合适的
公开(公告)号：EP1667980A1
公开(公告)日：2006-06-14
申请号：EP04765544.4
申请日：2004-09-23
申请人： Novartis AG , Novartis Pharma GmbH
发明人： FINK, Cynthia, Anne , PEREZ, Lawrence, Blas , RAMSEY, Timothy, Michael , YUSUFF, Naeem , VERSACE, Richard, William , BATT, David, Bryant , SABIO, Michael, Lloyd , KIM, Sunkyu
IPC分类号： C07D217/22 , C07D401/04 , C07D405/04 , C07D405/14 , C07D401/14 , C07D413/14 , C07D409/14 , C07D413/04 , C07D413/10 , C07D417/14 , A61K31/4725 , A61P35/00
CPC分类号： C07D401/04 , C07D217/22 , C07D401/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/14 , C07D491/10 , C07D491/113
摘要： This invention relates to compounds of formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.
-
公开(公告)号：EP1651633A1
公开(公告)日：2006-05-03
申请号：EP04763455.5
申请日：2004-07-23
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： C07D401/06 , C07D223/12 , A61K31/55 , A61P35/00
CPC分类号： C07D401/06 , C07D223/12
摘要： This invention relates to certain substituted lactam compounds of the formula (I), particularly caprolactam compounds, which are useful for the treatment of cancer.
-
公开(公告)号：EP2004165A2
公开(公告)日：2008-12-24
申请号：EP07781283.2
申请日：2007-04-04
发明人： BURKE, Gregory , CARAVATTI, Giorgio , LANE, Heidi , LINNARTZ, Ronald, Richard , VERSACE, Richard, William
IPC分类号： A61K31/136 , A61K31/275 , A61K31/36 , A61K31/381 , A61K31/454 , A61K31/519 , A61K31/553 , A61K31/7072 , A61K31/7076 , A61K45/06 , A61P35/00 , A61P35/02 , A61P35/04
CPC分类号： A61K31/454 , A61K31/136 , A61K31/275 , A61K31/36 , A61K31/381 , A61K31/519 , A61K31/553 , A61K31/7072 , A61K31/7076 , A61K45/06 , A61K2300/00
摘要： The invention relates to a combination comprising an Erb-B and VEGF receptor inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.
-
10.发明公开SUBSTITUTED CAPROLACTAM CARBONATES AND ETHERS AND THEIR USE AS ANTI-TUMOR AGENTS 有权取代碳酸己内酰胺和乙醚及其用途抗肿瘤活性
公开(公告)号：EP1282604A1
公开(公告)日：2003-02-12
申请号：EP01975824.2
申请日：2001-05-09
IPC分类号： C07D223/12 , A61K31/55 , A61P35/00
CPC分类号： C07D223/12
摘要： The present invention relates to certain substituted caporlactam carbonate and ether compounds of following formula (I): pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process for making said compounds.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.016 秒)
